Del Mar Pharmaceuticals Plans Clinical Trials for GBM Treatment
DMP estimates that the market for treating GBM patients post front-line therapy exceeds US$200 million annually in North America.
DMP estimates that the market for treating GBM patients post front-line therapy exceeds US$200 million annually in North America.
Glioblastoma multiforme (GBM), the aggressive brain tumor that took Sen. Kennedy’s life, is one of the deadliest brain tumors that can occur in both adults and children.
Copyright © 2024 | WordPress Theme by MH Themes